SRF-funded researcher Dr. Howard Chang shares a breakthrough discovery he & his collaborators made, shedding light on why women are more likely than men to develop autoimmune diseases like #scleroderma,...
Read More
Nearly 90% of those with scleroderma have Raynaud’s symptoms. This is why Raynaud’s can be a “red flag” that helps lead to diagnosis and treatment of scleroderma. And for Aneila, dx…
February is Rare Disease Awareness Month. It's an opportunity for us to come together and raise awareness about what it means to live with a rare disease like #scleroderma. To...
Read More
Dr. Gordon will have oversight over the SRF’s global clinical trial program CONQUEST and will contribute to the research program across the SRF portfolio San Francisco, CA (January 25, 2024)…
In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing...
Read More
FDA clears IND to launch CONQUEST trial platform with initial focus on Interstitial Lung Disease Secondary to Scleroderma (SSc-ILD) SCLERODERMA RESEARCH FOUNDATION (SRF) holds the IND as trial Sponsor Sanofi...
Read More
In our last eNews of the year, read about exciting research updates, like how CONQUEST has recieved the FDA's OK to proceed, and how CONQUER has already result in 6...
Read More
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
What makes researchers so dedicated to finding a cure? SRF-Funded investigator, Dr. Howard Chang of Stanford University, shares his perspective on making an impact through scleroderma research.
Read More
Lorena was diagnosed with scleroderma in 2021, and she wants a cure found for this disease. “When I went to see my scleroderma doctor for the first time, I was…
